Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma

Blood

Volumn 110, Issue 2, 2007, Pages 670-677

  Damm Welk, Christine ^a   Busch, Kerstin ^a   Burkhardt, Birgit ^a   Schieferstein, Jutta ^a   Viehmann, Susanne ^a   Oschlies, Ilske ^b   Klapper, Wolfram ^b   Zimmermann, Martin ^a   Harbott, Jochen ^a   Reiter, Alfred ^a,c   Woessmann, Willi ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ANAPLASTIC LARGE CELL LYMPHOMA; ARTICLE; BLOOD; BONE MARROW; CANCER DIAGNOSIS; CANCER STAGING; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FUSION GENE; HISTOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NPM ALK GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE;

EID: 34447316725     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-02-066852     Document Type: Article

References (37)

1. Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005;131:39-49.
2. Brugieres L, Deley MC, Pacquement H, et al. CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92:3591-3598.
3. Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol. 1994;12:899-908.
4. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 2001;97:3699-3706.
5. Williams DM, Hobson R, Imeson J, et al. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens. Br J Haematol. 2002;117:812-820.
6. Sandlund JT, Pui CH, Roberts WM, et al. Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood. 1994;84:2467-2471.
7. Le Deley MC, Brugieres L, Williams DM, Reiter A. Prognostic factors in childhood anaplastic large cell lymphoma (ALCL): results of the European Intergroup Study [abstract]. Blood. 2006;108:581a.
8. Schmitt C, Delsol G, Brugieres L, et al. Lymphohistiocytic variant of anaplastic large cell lymphoma in children and adolescents: a long-term study by the French society of pediatric cancer-lymphoma group. Pediatr Blood Cancer. 2006;46:841-842.
9. Schnell R, Staak O, Borchmann P, et al. A phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res. 2002;8:1779-1786.
10. Woessmann W, Peters C, Lenhard M, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents: a Berlin-Frankfurt-Munster group report. Br J Haematol. 2006;133:176-182.
11. Zhang M, Yao Z, Zhang Z, et al. Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. Blood. 2006;108:705-710.
12. Drexler HG, Gignac SM, von Wasielewski R, Werner M, Dirks WG. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia. 2000;14:1533-1559.
13. Perkins SL, Pickering D, Lowe EJ, et al. Childhood anaplastic large cell lymphoma has a high incidence of ALK gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridisation: a genetic and pathological correlation. Br J Haematol. 2005;131:624-627.
14. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681-3695.
15. Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 2001;20:5623-5637.
16. Kutok JL, Aster JC. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J Clin Oncol. 2002;20:3691-3702.
17. Pulford K, Morris SW, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol. 2004;199:330-358.
18. Downing JR, Shurtleff SA, Zielenska M, et al. Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptasepolymerase chain reaction. Blood. 1995;85:3416-3422.
19. Mussolin L, Pillon M, d'Amore ES, et al. Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma. Leukemia. 2005;19:1643-1647.
20. Gabert J, Beillard E, van dV V, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe Against Cancer program. Leukemia. 2003;17:2318-2357.
21. Viehmann S, Teigler-Schlegel A, Bruch J, et al. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement. Leukemia. 2003;17:1130-1136.
22. Brugieres L, Le Deley MC, Rosolen A, et al. Anaplastic large cell lympoma (ALCL) in children: equal efficacy but greater toxicity of chemotherapy including Methotrexate (MTX) 1g/m2 in 24-hour infusion with intrathecal injection (IT) than chemotherapy with MTX 3g/m2 in 3-hour infusion without IT: results of the ALCL99-R1 randomised trial [abstract]. Blood. 2006;108:122a.
23. Beillard E, Pallisgaard N, van dV V, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): a Europe against cancer program. Leukemia. 2003;17:2474-2486.
24. Lamant L, Meggetto F, al ST, et al. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease: comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood. 1996;87:284-291.
25. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994;263:1281-1284.
26. Wilda M, Bruch J, Harder L, et al. Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt's lymphoma in children. Leukemia. 2004;18:584-588.
27. Greenwood M. A report on the natural duration of cancer. In: Reports on Public Health and Medical Subjects, Vol 33, appendix 1. London, United Kingdom: Her Majesty's Stationary Office; 1926:1-26.
28. Kaplan EL. Non-parametric estimation from incomplete observations. Am Stat Assos. 1958;53:457-481.
29. Mantel E. Evaluation of survival data and tow new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
30. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York, NY: John Wiley; 1980.
31. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988:1141-1154.
32. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-200.
33. Coustan-Smith E, Sancho J, Hancock ML, et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood. 2002;100:2399-2402.
34. van der Velden VH, Jacobs DC, Wijkhuijs AJ, et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia. 2002;16:1432-1436.
35. Lossos IS, Czerwinski DK, Wechser MA, Levy R. Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia. 2003;17:789-795.
36. Fraga M, Brousset P, Schlaifer D, et al. Bone marrow involvement in anaplastic large cell lymphoma: immunohistochemical detection of minimal disease and its prognostic significance. Am J Clin Pathol. 1995;103:82-89.
37. Costes V, Duchayne E, Taib J, et al. Intrasinusoidal bone marrow infiltration: a common growth pattern for different lymphoma subtypes. Br J Haematol. 2002;119:916-922.